Company Overview of China Manufacturer - Nanjing Nuoyuan Medical Devices Co., Ltd.

Info marked by is verified by CTI

Supplier Homepage About Us

About Us

Contact Supplier

Mr. Yangliu

Company Profile

General Information

Trade Capacity

Production Capacity

R&D Capacity

Company Show

Company Profile

Inquiry Basket

Nanjing Nuoyuan Medical Devices Co., Ltd.

360° Virtual Tour Book a Factory Tour

	Business Type:	Manufacturer/Factory & Trading Company
	Main Products:	‪Endoscope‬ , ‪Indocyanine Green‬ , ‪2CMOS Camera‬ , ‪3D4K Fluorescence Endoscope‬ , ‪2D4K Fluorescence ...‬
	Year of Establishment:	2011-04-11
	Number of Employees:	180
	Management System Certification:	ISO9001:2015, ISO45001:2018, ISO14001, Others
	Address:	Nanjing, Jiangsu, China

CTI Audit Report No. :

QIP-ASI254198 Verify Now | Read Free Report

Nanjing Nuoyuan Medical Devices Co., Ltd. (hereinafter referred to as Nuoyuan Medical or the Company) was founded in 2011. It stands as a nationally recognized high-tech enterprise, renowned for its profound innovative capabilities, which encompass the entire spectrum of research and development, production, and marketing of cutting-edge medical devices and pioneering targeted contrast agent drugs. The company′s core mission revolves around furnishing comprehensive solutions for the precision diagnosis and treatment of cancer, with a special focus on pivotal technologies such as Molecular Fluorescence, Raman Spectroscopy, Artificial Intelligence, Computer-Aided Drug Design (CADD), and AI-facilitated drug design. As a testament to its commitment to innovation, Nuoyuan Medical boasts an extensive product pipeline.

Securing authoritative recognition for scientific research and innovation prowess

From the very inception of Nuoyuan Medical, it has garnered significant esteem from both the national and Jiangsu provincial governments. The company boasts a portfolio of 79 domestic and international invention patents that span the entire device and its core components.

Competitive advantages of Core products

Nuoyuan Medical continues to explore minimally invasive and precise treatment solutions, integrating exclusive microwave ablation simulation technology, conformal tumor ablation technology, and carbonization regulation technology to effectively solve clinical problems in tumor microwave treatment and achieve precise ablation.

Nuoyuan Medical focuses on the development of artificial intelligence medical device products. The artificial intelligence assisted Automatic Digital Pathological Analysis and Scanning System (ADPASS) developed by Nuoyuan Medical has a high-negative pathological samples discriminating rate, significantly improving the efficiency and accuracy of the diagnosis process.

Domestic and International simultaneous market spreading

Nuoyuan Medical is in line with the Healthy China strategy and has developed a series of products that have been used in over 500 large hospitals across the country. At the same time, Nuoyuan Medical is a strategic partner of international leading companies such as B. Braun Melsungen, whose multiple products are Originally Designed and Manufactured by Nuoyuan Medical. Nuoyuan Medical is simultaneously promoting the registration of its products in China, the United States and Europe. Until now the company has completed multiple system certifications such as 13485/9001, and multiple products are currently undergoing FDA registration in the United States and CE certification in the European Union. And looking forward to enter the global market.

The innovative model of "combining pharmaceuticals and devices"

Nuoyuan Medical has utilized its deep accumulation in drug research and development to develop an internationally first-class broad-spectrum fluorescent contrast agent "Indocyanine green". At the same time, AI assisted and CADD technology have been applied to develop multiple novel targeting fluorescent contrast agents for multiple typical tumor markers. Among them, the new generation of targeted "Pemefolacianine" fluorescent contrast agents have high specificity compared to similar fluorescent contrast agents in the United States, and can significantly reduce the false positive rate. This will significantly improve the accuracy of tumor surgical resection, thereby improving the prognosis and patients′ life quality. At present, the "Pemefolacianine" fluorescent contrast agent has been granted international invention patents, in China, the United States, Europe, and Japan.